查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1609561

融合切片检查市场规模、份额、趋势分析报告：按切片检查途径、最终用途、地区、细分市场预测，2025-2030 年

Fusion Biopsy Market Size, Share & Trends Analysis Report By Biopsy Route (Transrectal, Transperineal), By End Use (Hospitals, Diagnostic Centers, Ambulatory Care Centers), By Region (North America, Asia Pacific), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

融合切片检查市场的成长和趋势

根据Grand View Research, Inc.最新报告，预计2030年全球融合切片检查市场规模将达12亿美元，2025年至2030年复合年增长率为8.6%。

前列腺癌盛行率不断上升、对标靶切片检查的需求不断增长以及多波长 MRI 在前列腺癌治疗中的使用不断增加，预计将在预测期内推动市场发展。此外，人们对常规治疗性介入价值的认识不断提高和新的报销措施等因素预计将推动融合切片检查市场的需求。

与 TRUS切片检查、PSA 检测和直肠指检等其他传统技术相比，标靶融合切片检查由于其在描绘前列腺病变方面具有更高的敏感性和特异性，预计将有助于市场成长。融合切片检查系统在诊断进行性肿瘤方面的可靠性和可重复性预计将使其成为前列腺切片检查的标准工具。越来越多的放射科医生获得前列腺 MRI 解读方面的专业知识，加上 PI-RADS 和 Gleason 评分等标准影像分类系统的引入，导致了靶向 MR/超音波融合切片检查系统的采用，我们正在提高利用率。

政府在资助前列腺癌相关研究、传播意识和实施大规模筛检计画方面的倡议预计将在市场成长中发挥关键作用。市场参与企业采取的成长策略包括伙伴关係、产品发布、参加贸易展览和会议以及收购，以推动和维持这个竞争激烈的领域的成长。

融合切片检查市场报告亮点

  • 作为前列腺融合切片检查的黄金标准和常用方法，经直肠部分在2024年占据最大的市场占有率。
  • 由于其安全性、诊断效率和进入腹侧前列腺区域的能力，经直肠段预计在预测期内将以最快的速度增长。
  • 由于教学医院MR/ 美国标靶融合切片检查系统的采购率增加等因素，医院部门在2024年占据了最大的收益占有率。
  • 预计诊断中心细分市场将在预测期内大幅扩张。等待时间的减少、成本效率和报销模式的发展是推动该细分市场成长的因素。
  • 北美在 2024 年占据最大的市场占有率，预计在预测期内将保持其主导地位。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章融合切片检查市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 渗透率和成长前景图
  • 产业价值链分析
    • 赎回框架
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 融合切片检查市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 主要交易及策略联盟分析
    • 打入市场策略
    • COVID-19 影响分析

第四章融合切片检查市场：按切片检查途径的估计和趋势分析

  • 定义和范围
    • 经直肠
    • 经会阴
  • 2024年及2030年切片检查途径市场占有率
  • 细分仪表板
  • 切片检查途径分類的融合切片检查市场前景
  • 2018-2030年市场规模、预测及趋势分析
    • 经直肠
    • 经会阴

第五章融合切片检查市场：最终用途的估计和趋势分析

  • 定义和范围
    • 医院
    • 诊断中心
    • 门诊治疗中心
  • 2024 年及 2030 年最终用途市场占有率
  • 细分仪表板
  • 按最终用途分類的融合切片检查市场前景
  • 2018-2030年市场规模、预测及趋势分析
    • 医院
    • 诊断中心
    • 门诊治疗中心

第六章融合切片检查市场：区域、估计和趋势分析

  • 2024 年及 2030 年按地区分類的市场占有率
  • 区域市场仪表板
  • 区域市场简介
  • 2024 年按地区和主要参与企业市场占有率
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东/非洲
  • 依因素进行 SWOT 分析（政治/法律、经济技术）
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东/非洲
  • 2022-2030 年市场规模、预测、趋势分析：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 泰国
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
    • 创新者
    • 市场领导者
    • 参与企业
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 2024年主要企业市场占有率分析
  • 上市公司
    • 公司市场分析（收益、地理分布、产品系列、主要服务业、主要联盟）
    • 企业市场占有率/地区排名
    • 竞争仪表板分析
  • 私人公司
    • 主要新兴企业/技术创新公司/创新者名单
    • 资金筹措前景
    • 区域网路图
    • 公司市场分析（地理位置、产品系列、主要联盟、产业经验）
    • 供应商排名
    • 主要企业公告
    • Eigen
    • Koninklijke Philips NV
    • Hitachi, Ltd.
    • MedCom
    • ESAOTE SPA
    • KOELIS
    • Focal Healthcare
    • GeoScan Medical
    • UC-Care Medical Systems Ltd.
Product Code: GVR-4-68038-844-2

Fusion Biopsy Market Growth & Trends:

The global fusion biopsy market size is expected to reach USD 1.2 billion by 2030, registering a CAGR of 8.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of prostate cancer, growing demand for targeted biopsy, and the rising utilization rate of multipara metric MRI in prostate cancer care are factors expected to drive the market during the forecast period. Moreover, factors such as rising awareness of the value of routine therapeutic interventions and emerging reimbursement policies are projected to drive demand in the market for fusion biopsy.

The high sensitivity and specificity of targeted fusion biopsy in delineating prostate lesions compared to other traditional technologies such as TRUS biopsy, PSA test, or Digital Rectal Examination is expected to contribute to the market growth. The reliability & reproducibility of the fusion biopsy system in the diagnosis of aggressive tumors is expected to make it a standard tool in prostate biopsy. An increasing number of radiologists gaining expertise in interpreting prostate MRI, coupled with the implementation of standard image grading systems such as PI-RADS and Gleason score, has increased the utilization rate of targeted MR/Ultrasound fusion biopsy systems.

The increasing number of government initiatives in terms of funding research, spreading awareness, and conducting mass screening programs related to prostate cancer are expected to play a crucial in the growth of the market. Some of the growth strategies adopted by market players include partnerships, product launches, participation in trade events and conferences, and acquisitions to drive and sustain growth in this highly competitive space.

Fusion Biopsy Market Report Highlights:

  • The transrectal segment held the largest market share in 2024, as it is the gold standard and commonly used method of prostate fusion biopsy
  • The transperineal segment is expected to grow at the fastest rate during the forecast period owing to the safety, diagnostic efficiency, and ability to access ventral prostate areas
  • The hospital segment accounted for the largest revenue share in 2024, owing to factors such as the increasing procurement rate of MR/US targeted fusion biopsy systems in teaching hospitals
  • The diagnostics centers segment is expected to expand at a significant rate over the forecast period. Shorter wait times, cost efficiency, and developing reimbursement paradigm are the factors expected to drive the growth of this segment
  • North America held the largest market share in 2024 and is anticipated to maintain its dominance over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Biopsy route
    • 1.1.2. End-use
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for Primary Interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for Primary Interviews in Latin America
      • 1.3.5.5. Data for Primary Interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Biopsy route outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Fusion Biopsy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Industry Value Chain Analysis
    • 3.3.1. Reimbursement framework
  • 3.4. Market Dynamics
    • 3.4.1. Market Driver Analysis
      • 3.4.1.1. Increasing prevalence of prostate cancer
      • 3.4.1.2. Technological advancements in fusion imaging modalities
      • 3.4.1.3. Increasing funds and investments by public and private sector
    • 3.4.2. Market Restraint Analysis
      • 3.4.2.1. High cost of fusion biopsy system
      • 3.4.2.2. Liquid biopsy system
  • 3.5. Fusion Biopsy Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic Landscape
    • 3.5.3. Major deals & strategic alliances analysis
    • 3.5.4. Market entry strategies
    • 3.5.5. Covid-19 Impact Analysis

Chapter 4. Fusion Biopsy Market: Biopsy Route Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Transrectal
    • 4.1.2. Transperineal
  • 4.2. Biopsy Route Market Share, 2024 & 2030
  • 4.3. Segment Dashboard
  • 4.4. Global Fusion Biopsy Market by Biopsy Route Outlook
  • 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.5.1. Transrectal
      • 4.5.1.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 4.5.2. Transperineal
      • 4.5.2.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)

Chapter 5. Fusion Biopsy Market: End-use Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Hospitals
    • 5.1.2. Diagnostic centers
    • 5.1.3. Ambulatory care centers
  • 5.2. End-use, 2024 & 2030
  • 5.3. Segment Dashboard
  • 5.4. Fusion Biopsy Market by End-use Outlook
  • 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.5.1. Hospitals
      • 5.5.1.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. Diagnostic centers
      • 5.5.2.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. Ambulatory care centers
      • 5.5.3.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Fusion Biopsy Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Regional Market Snapshot
  • 6.4. Regional Market Share and Leading Players, 2024
    • 6.4.1. North America
    • 6.4.2. Europe
    • 6.4.3. Asia Pacific
    • 6.4.4. Latin America
    • 6.4.5. Middle East and Africa
  • 6.5. SWOT Analysis by Factor (Political & Legal, Economic and Technological)
    • 6.5.1. North America
    • 6.5.2. Europe
    • 6.5.3. Asia Pacific
    • 6.5.4. Latin America
    • 6.5.5. Middle East and Africa
  • 6.6. Market Size, & Forecasts and Trend Analysis, 2022 to 2030:
  • 6.7. North America
    • 6.7.1. U.S.
      • 6.7.1.1. Key Country Dynamics
      • 6.7.1.2. Regulatory Landscape/Reimbursement Scenario
      • 6.7.1.3. Competitive Landscape
      • 6.7.1.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Canada
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Landscape/Reimbursement Scenario
      • 6.7.2.3. Competitive Landscape
      • 6.7.2.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. Mexico
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Landscape/Reimbursement Scenario
      • 6.7.3.3. Competitive Landscape
      • 6.7.3.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.8. Europe
    • 6.8.1. UK
      • 6.8.1.1. Key Country Dynamics
      • 6.8.1.2. Regulatory Landscape/Reimbursement Scenario
      • 6.8.1.3. Competitive Landscape
      • 6.8.1.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.8.2. Germany
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Landscape/Reimbursement Scenario
      • 6.8.2.3. Competitive Landscape
      • 6.8.2.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.8.3. France
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Landscape/Reimbursement Scenario
      • 6.8.3.3. Competitive Landscape
      • 6.8.3.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.8.4. Italy
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Landscape/Reimbursement Scenario
      • 6.8.4.3. Competitive Landscape
      • 6.8.4.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.8.5. Spain
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Landscape/Reimbursement Scenario
      • 6.8.5.3. Competitive Landscape
      • 6.8.5.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.8.6. Denmark
      • 6.8.6.1. Key Country Dynamics
      • 6.8.6.2. Regulatory Landscape/Reimbursement Scenario
      • 6.8.6.3. Competitive Landscape
      • 6.8.6.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.8.7. Sweden
      • 6.8.7.1. Key Country Dynamics
      • 6.8.7.2. Regulatory Landscape/Reimbursement Scenario
      • 6.8.7.3. Competitive Landscape
      • 6.8.7.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.8.8. Norway
      • 6.8.8.1. Key Country Dynamics
      • 6.8.8.2. Regulatory Landscape/Reimbursement Scenario
      • 6.8.8.3. Competitive Landscape
      • 6.8.8.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.9. Asia Pacific
    • 6.9.1. Japan
      • 6.9.1.1. Key Country Dynamics
      • 6.9.1.2. Regulatory Landscape/Reimbursement Scenario
      • 6.9.1.3. Competitive Landscape
      • 6.9.1.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.9.2. China
      • 6.9.2.1. Key Country Dynamics
      • 6.9.2.2. Regulatory Landscape/Reimbursement Scenario
      • 6.9.2.3. Competitive Landscape
      • 6.9.2.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.9.3. India
      • 6.9.3.1. Key Country Dynamics
      • 6.9.3.2. Regulatory Landscape/Reimbursement Scenario
      • 6.9.3.3. Competitive Landscape
      • 6.9.3.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.9.4. South Korea
      • 6.9.4.1. Key Country Dynamics
      • 6.9.4.2. Regulatory Landscape/Reimbursement Scenario
      • 6.9.4.3. Competitive Landscape
      • 6.9.4.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.9.5. Thailand
      • 6.9.5.1. Key Country Dynamics
      • 6.9.5.2. Regulatory Landscape/Reimbursement Scenario
      • 6.9.5.3. Competitive Landscape
      • 6.9.5.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.9.6. Australia
      • 6.9.6.1. Key Country Dynamics
      • 6.9.6.2. Regulatory Landscape/Reimbursement Scenario
      • 6.9.6.3. Competitive Landscape
      • 6.9.6.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.10. Latin America
    • 6.10.1. Brazil
      • 6.10.1.1. Key Country Dynamics
      • 6.10.1.2. Regulatory Landscape/Reimbursement Scenario
      • 6.10.1.3. Competitive Landscape
      • 6.10.1.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.10.2. Argentina
      • 6.10.2.1. Key Country Dynamics
      • 6.10.2.2. Regulatory Landscape/Reimbursement Scenario
      • 6.10.2.3. Competitive Landscape
      • 6.10.2.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.11. MEA
    • 6.11.1. South Africa
      • 6.11.1.1. Key Country Dynamics
      • 6.11.1.2. Regulatory Landscape/Reimbursement Scenario
      • 6.11.1.3. Competitive Landscape
      • 6.11.1.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.11.2. Saudi Arabia
      • 6.11.2.1. Key Country Dynamics
      • 6.11.2.2. Regulatory Landscape/Reimbursement Scenario
      • 6.11.2.3. Competitive Landscape
      • 6.11.2.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.11.3. UAE
      • 6.11.3.1. Key Country Dynamics
      • 6.11.3.2. Regulatory Landscape/Reimbursement Scenario
      • 6.11.3.3. Competitive Landscape
      • 6.11.3.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
    • 6.11.4. Kuwait
      • 6.11.4.1. Key Country Dynamics
      • 6.11.4.2. Regulatory Landscape/Reimbursement Scenario
      • 6.11.4.3. Competitive Landscape
      • 6.11.4.4. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competitive Categorization
    • 7.2.1. Innovators
    • 7.2.2. Market leaders
    • 7.2.3. Emerging players
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
  • 7.4. Public Companies
    • 7.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 7.4.2. Company market share/ranking, by region
    • 7.4.3. Competitive dashboard analysis
      • 7.4.3.1. Market differentiators
      • 7.4.3.2. Synergy analysis: major deals and strategic alliances
  • 7.5. Private Companies
    • 7.5.1. List of key emerging companies/technology disruptors/innovators
    • 7.5.2. Funding outlook
    • 7.5.3. Regional network map
    • 7.5.4. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
    • 7.5.5. Supplier ranking
    • 7.5.6. Key company profiled
    • 7.5.7. Eigen
      • 7.5.7.1. Company overview
      • 7.5.7.2. Financial performance
      • 7.5.7.3. Product benchmarking
      • 7.5.7.4. Strategic initiatives
    • 7.5.8. Koninklijke Philips N.V.
      • 7.5.8.1. Company overview
      • 7.5.8.2. Financial performance
      • 7.5.8.3. Product benchmarking
      • 7.5.8.4. Strategic initiatives
    • 7.5.9. Hitachi, Ltd.
      • 7.5.9.1. Company overview
      • 7.5.9.2. Financial performance
      • 7.5.9.3. Product benchmarking
      • 7.5.9.4. Strategic initiatives
    • 7.5.10. MedCom
      • 7.5.10.1. Company overview
      • 7.5.10.2. Financial performance
      • 7.5.10.3. Product benchmarking
      • 7.5.10.4. Strategic initiatives
    • 7.5.11. ESAOTE SPA
      • 7.5.11.1. Company overview
      • 7.5.11.2. Financial performance
      • 7.5.11.3. Product benchmarking
      • 7.5.11.4. Strategic initiatives
    • 7.5.12. KOELIS
      • 7.5.12.1. Company overview
      • 7.5.12.2. Financial performance
      • 7.5.12.3. Product benchmarking
      • 7.5.12.4. Strategic initiatives
    • 7.5.13. Focal Healthcare
      • 7.5.13.1. Company overview
      • 7.5.13.2. Financial performance
      • 7.5.13.3. Product benchmarking
      • 7.5.13.4. Strategic initiatives
    • 7.5.14. GeoScan Medical
      • 7.5.14.1. Company overview
      • 7.5.14.2. Financial performance
      • 7.5.14.3. Product benchmarking
      • 7.5.14.4. Strategic initiatives
    • 7.5.15. UC-Care Medical Systems Ltd.
      • 7.5.15.1. Company overview
      • 7.5.15.2. Financial performance
      • 7.5.15.3. Product benchmarking
      • 7.5.15.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America fusion biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 4 North America fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 U.S. fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 6 U.S. fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 7 Canada fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 8 Canada fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 Europe fusion biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 11 Europe fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 12 U.K. fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 13 U.K. fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Germany fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 15 Germany fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 Italy fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 17 Italy fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 18 France fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 19 France fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Spain fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 21 Spain fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 Denmark fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 23 Denmark fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 Sweden fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 25 Sweden fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Norway fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 27 Norway fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific fusion biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Japan fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 32 Japan fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 India fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 34 India fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 China fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 36 China fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 Thailand fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 38 Thailand fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 39 South Korea fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 40 South Korea fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 Australia fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 42 Australia fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Latin America fusion biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 44 Latin America fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 45 Latin America fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 46 Brazil fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 47 Brazil fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 48 Mexico fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 49 Mexico fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 Argentina fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 51 Argentina fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 52 MEA fusion biopsy market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 54 MEA fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 55 South Africa fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 56 South Africa fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 UAE fusion biopsy market, by biopsy route, 2018 - 2030 (USD Million)
  • Table 60 UAE fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait fusion biopsy market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Kuwait fusion biopsy market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary Interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Fusion biopsy market: market outlook
  • Fig. 14 Fusion biopsy market competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Fusion biopsy market driver impact
  • Fig. 20 Fusion biopsy market restraint impact
  • Fig. 21 Fusion biopsy market strategic initiatives analysis
  • Fig. 22 Fusion biopsy market: biopsy route movement analysis
  • Fig. 23 Fusion biopsy market: biopsy route outlook and key takeaways
  • Fig. 24 Transrectal market estimates and forecast, 2018 - 2030
  • Fig. 25 Transperineal market estimates and forecast, 2018 - 2030
  • Fig. 26 Fusion biopsy market: end-use movement analysis
  • Fig. 27 Fusion biopsy market: end-use outlook and key takeaways
  • Fig. 28 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 29 Diagnostic centers market estimates and forecast, 2018 - 2030
  • Fig. 30 Ambulatory care centers market estimates and forecast, 2018 - 2030
  • Fig. 31 Fusion biopsy market: Regional movement analysis
  • Fig. 32 Fusion biopsy market: regional outlook and key takeaways
  • Fig. 33 Fusion biopsy market share and leading players
  • Fig. 34 North America market share and leading players
  • Fig. 35 Europe market share and leading players
  • Fig. 36 Asia Pacific market share and leading players
  • Fig. 37 Latin America market share and leading players
  • Fig. 38 Middle East & Africa market share and leading players
  • Fig. 39 North America: SWOT
  • Fig. 40 Europe SWOT
  • Fig. 41 Asia Pacific SWOT
  • Fig. 42 Latin America SWOT
  • Fig. 43 MEA SWOT
  • Fig. 44 North America, by country
  • Fig. 45 North America
  • Fig. 46 North America market estimates and forecast, 2018 - 2030
  • Fig. 47 U.S.
  • Fig. 48 U.S. market estimates and forecast, 2018 - 2030
  • Fig. 49 Canada
  • Fig. 50 Canada market estimates and forecast, 2018 - 2030
  • Fig. 51 Europe
  • Fig. 52 Europe. market estimates and forecast, 2018 - 2030
  • Fig. 53 UK
  • Fig. 54 UK market estimates and forecast, 2018 - 2030
  • Fig. 55 Germany
  • Fig. 56 Germany market estimates and forecast, 2018 - 2030
  • Fig. 57 France
  • Fig. 58 France market estimates and forecast, 2018 - 2030
  • Fig. 59 Italy
  • Fig. 60 Italy market estimates and forecast, 2018 - 2030
  • Fig. 61 Spain
  • Fig. 62 Spain market estimates and forecast, 2018 - 2030
  • Fig. 63 Switzerland
  • Fig. 64 Switzerland market estimates and forecast, 2018 - 2030
  • Fig. 65 Belgium
  • Fig. 66 Belgium market estimates and forecast, 2018 - 2030
  • Fig. 67 Asia Pacific
  • Fig. 68 Asia Pacific market estimates and forecast, 2018 - 2030
  • Fig. 69 China
  • Fig. 70 China market estimates and forecast, 2018 - 2030
  • Fig. 71 Japan
  • Fig. 72 Japan market estimates and forecast, 2018 - 2030
  • Fig. 73 India
  • Fig. 74 India market estimates and forecast, 2018 - 2030
  • Fig. 75 Thailand
  • Fig. 76 Thailand. market estimates and forecast, 2018 - 2030
  • Fig. 77 South Korea
  • Fig. 78 South Korea market estimates and forecast, 2018 - 2030
  • Fig. 79 Australia
  • Fig. 80 Australia. market estimates and forecast, 2018 - 2030
  • Fig. 81 Latin America
  • Fig. 82 Latin America market estimates and forecast, 2018 - 2030
  • Fig. 83 Brazil
  • Fig. 84 Brazil market estimates and forecast, 2018 - 2030
  • Fig. 85 Mexico
  • Fig. 86 Mexico market estimates and forecast, 2018 - 2030
  • Fig. 87 Argentina
  • Fig. 88 Argentina market estimates and forecast, 2018 - 2030
  • Fig. 89 Middle East and Africa
  • Fig. 90 Middle East and Africa. market estimates and forecast, 2018 - 2030
  • Fig. 91 South Africa
  • Fig. 92 South Africa market estimates and forecast, 2018 - 2030
  • Fig. 93 Saudi Arabia
  • Fig. 94 Saudi Arabia market estimates and forecast, 2018 - 2030
  • Fig. 95 UAE
  • Fig. 96 UAE market estimates and forecast, 2018 - 2030
  • Fig. 97 Participant categorization- fusion biopsy market
  • Fig. 98 Market share of key market players- fusion biopsy market